In a report released yesterday, Tiago Fauth from Credit Suisse maintained a Hold rating on Argenx Se (ARGX), with a price target of $215.00. The company’s shares closed last Monday at $270.35.
According to TipRanks.com, Fauth is a 3-star analyst with an average return of 7.8% and a 69.2% success rate. Fauth covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Apellis Pharmaceuticals, and Ascendis Pharma.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $262.91.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
